Trial Profile

Study of the Benefit of Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma (HCC)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary)
Indications Carcinoma; Liver cancer
Focus Therapeutic Use
Acronyms Ta-Len-Tra

Most Recent Events

07 Apr 2025 Planned End Date changed from 1 Jul 2027 to 1 Apr 2027.
07 Apr 2025 Planned primary completion date changed from 1 Dec 2026 to 1 Apr 2027.
07 Apr 2025 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com